William Ho has served as President, CEO and Director of IN8bio since its inception. Mr. Ho has worked in the biotechnology industry for 21 years. Prior to the founding of IN8bio, Mr. Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, Mr. Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio, and served as its Public Investment Director since 2010. Previously, Mr. Ho served as a Senior Equity Research Analyst at Bank of America and an Equity Research Analyst at Piper Jaffray & Co., covering the biotechnology and life-science tools sectors. Earlier in his career, Mr. Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. Mr. Ho received his MBA from the University of Notre Dame and a B.S. in Biochemistry from McMaster University.